3D Signatures Inc. to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
January 25 2017 - 4:30PM
3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the
"Company" or "3DS"), today announced that its CEO, Jason Flowerday,
will present an update on the Company’s business at the Noble
Financial Capital Markets’ 13th Annual Investor Conference on
Tuesday, January 31 at 1:30 p.m. Eastern Time in Boca Raton,
Florida.
Investors attending the conferences who would
like to schedule a 1-on-1 meeting with 3D Signatures may do so by
contacting their Noble representative. The presentation will be
webcast live and archived for 120 days on the Company's website at
http://www.3dsignatures.com in the Investors section.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is
a personalized medicine company with a proprietary software
platform based on the three-dimensional analysis of chromosomal
signatures. The technology is well developed and supported by 20
clinical studies on over 2,000 patients on 13 different cancers and
Alzheimer’s disease. Depending on the desired application, this
platform technology can measure the stage of disease, rate of
progression of disease, drug efficacy, and drug toxicity. The
technology is designed to predict the course of disease and to
personalize treatment for the individual patient. For more
information, visit the Company’s new website at
http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking
statements that are subject to risks and uncertainties.
Forward-looking statements involve known and unknown risks,
uncertainties, and other factors that could cause the actual
results of the Company to be materially different from the
historical results or from any future results expressed or implied
by such forward-looking statements. All statements within, other
than statements of historical fact, are to be considered forward
looking. Although 3DS believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results or developments may differ materially from those in
forward-looking statements. Risk factors that could cause
actual results or outcomes to differ materially from the results
expressed or implied by forward-looking information include, among
other things: market demand; technological changes that could
impact the Company’s existing products or the Company’s ability to
develop and commercialize future products; competition; existing
governmental legislation and regulations and changes in, or the
failure to comply with, governmental legislation and
regulations; the ability to manage operating expenses, which
may adversely affect the Company’s financial condition; the
Company’s ability to successfully maintain and enforce its
intellectual property rights and defend third-party claims of
infringement of their intellectual property rights; adverse
results or unexpected delays in clinical trials; changes in
laws, general economic and business conditions; and changes in the
regulatory regime. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do not
assume any obligation to update any forward-looking
statements.
Neither the TSX Venture Exchange nor its
Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Stephen Kilmer
Investor Relations
647-872-4849
stephen.kilmer@3dsignatures.com
OR
Hugh Rogers
VP Corporate Finance
604-250-6162
investors@3dsignatures.com
3D Signatures (TSXV:DXD)
Historical Stock Chart
From Mar 2024 to Apr 2024
3D Signatures (TSXV:DXD)
Historical Stock Chart
From Apr 2023 to Apr 2024